Omega signs MOU to develop COVID-19 antibody test
London-listed (AIM:ODX ) has signed an MOU with three UK companies in order to jointly develop and manufacture a COVID-19 point-of-care antibody test.
The collaboration, which is in conjunction with the University of Oxford to form the “UK Rapid Test Consortium” forms part of the government's new five pillar national virus testing strategy.
The medical diagnostics company said the alliance was formed to produce an antibody test to determine whether people have developed immunity after contracting the coronavirus.
Shares in Omega Diagnostics were trading 72.73% higher at 19p a share.
Omega will work alongside Abingdon Health, BBI Solutions, and CIGA Healthcare for an initial six-month period to optimise a design for a potential accelerated scale-up to manufacturing rapid test for COVID-19.
Once the test reaches design freeze, procedures will be shared with the parties to enable manufacturing to be undertaken at each site, including at Omega's own site in Scotland.
"We are delighted to be part of this consortium and to support the Scottish and UK Governments' efforts to combat the Coronavirus pandemic,” said Colin King, CEO of Omega.
Follow News & Updates from here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.